Mild Cognitive Impairment
Also known as: MCI
Methodology & AI Transparency ⓘ
Mild Cognitive Impairment Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Some forgetfulness can be a normal part of aging.
- 2 Real-world patient consensus: Clinical coding for Mild Cognitive Impairment uses ICD-10 G30.4 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Primary evaluation for Mild Cognitive Impairment incorporates reversible metabolic/medication/sleep-apnea workup [Mild Cognitive Impairment G30.4] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Mild Cognitive Impairment: Homocysteine & Vitamin in Mild Cognitive Impairment (G30.4: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G30.4)) and TSH & Fasting in Mild Cognitive Impairment (G30.4: ApoB / HbA1c).
Ask our AI Specialists anything about Mild Cognitive Impairment
What Is Mild Cognitive Impairment?
Some forgetfulness can be a normal part of aging. However, some people have more memory problems than other people their age. This condition is called mild cognitive impairment, or MCI. People with MCI can take care of themselves and do their normal activities. MCI memory problems may include: Losing things often Forgetting to go to events and appointments Having more trouble coming up with words than other people of the same age Memory problems can also have other causes, including certain medicines and diseases that affect the blood vessels that supply the brain. Some of the problems brought on by these conditions can be managed or reversed.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in memory & cognition, Mild Cognitive Impairment (G30.4) involves cholinergic basal forebrain in Mild Cognitive Impairment (G30.4: depletion). Cross-referenced with NIH MeSH (Cognitive Dysfunction), progression correlates with shifts in Homocysteine & Vitamin in Mild Cognitive Impairment (G30.4: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G30.4)).
Common Symptoms & Clinical Signs
- • Losing things often
- • Forgetting to go to events and appointments
- • Presentation of Mild Cognitive Impairment (G30.4): slowed processing speed in Mild Cognitive Impairment (G30.4: compared with prior)
- • Secondary Mild Cognitive Impairment clinical sign: short-term recall difficulty in Mild Cognitive Impairment (G30.4: for recent conversations,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mild Cognitive Impairment Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G30.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Mild Cognitive Impairment (G30.4: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G30.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Mild Cognitive Impairment (G30.4: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G30.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Mild Cognitive Impairment (G30.4: Score) | >= 26 / 30 (G30.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mild Cognitive Impairment
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lecanemab Leqembi • RxCUI 2626147 | Amyloid Beta-directed Antibody | 87% | $2.9700 | $ 128.79 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mild Cognitive Impairment)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| GLP-1RA vs. Placebo: Which Works Better for Heart failure and mildly reduced or preserved ejection fraction? GLP-1RA reduce HF exacerbations and can play a role in reducing hospitalizations, improving patient's functional status, and significantly impacting the global healthcare burden of HF. International journal of cardiology • 2025-11-01 • Meta-Analysis | N = 4,474 | 99/100 | PMID 40623630 ↗ |
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the: What a 13,026-Participant Study Found We explore the emerging role of the nonsteroidal MRA finerenone as a new therapeutic opportunity to improve the risk of adverse heart and blood vessel outcomes in patients with HF and mildly reduced or preserved ejection. American journal of cardiovascular drugs : drugs, devices, and other interventions • 2025-07-15 • Phase III Randomized Trial | N = 13,026 | 96/100 | PMID 40055303 ↗ |
| New Insights on Efficacy of finerenone in patients with heart failure and mildly reduced or: What a 3,497-Participant Study Found Among patients with HFpEF/HFmrEF in FINEARTS-HF, higher baseline HR was associated with a higher risk of the primary outcome in patients with SR but not in those with AF. European journal of heart failure • 2026-05-02 • Phase III Randomized Trial | N = 3,497 | 96/100 | PMID 41771075 ↗ |
| Check Your Medicine Cabinet: Family Farmstead Dairy Announces Recall of Raw Mild Cheddar Cheese Due to Potential E. c WORCESTER, NY, October 15, 2026 - Family Farmstead Dairy of Worcester, NY is recalling specific lot of cheddar cheese because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with FDA Drug Recalls • 2026-10-15 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-2412744266 ↗ |
Mild Cognitive Impairment Patient Community & “People Like Me” Threads
Filter Mild Cognitive Impairment community threads and patient logs by age, biological sex, dosage, and treatment duration.